Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
1 finding from 1 review
- no estimate extracted1 study · 48 participantsVery low